Literature DB >> 10763141

Prognostic significance of CEA and CA 19-9 in colorectal cancer in Kuwait.

A I Behbehani1, H Al-Sayer, M Farghaly, N Kanawati, A Mathew, A al-Bader, A Van Dalen.   

Abstract

Preoperative CEA and CA 19-9 levels have been used in the past as prognostic indicators in colorectal cancer, but Dukes' stage is still considered to be the most important prognostic factor. Recent survival estimates may have been influenced by the fact that in the last decade adjuvant chemotherapy and postoperative irradiation have been included in the routine management of advanced-stage disease. In a heterogeneous Kuwaiti population higher reference levels (95th percentile) of CEA and CA 19-9 have been found than those usually employed. In the present study 62 patients with Dukes' stage B + C could be analyzed for two-year disease-free survival (DFS). Relapse was observed in 19 patients, 28 patients were disease free and 15 patients with censored observations were included. No significant difference in DFS was observed in Dukes' B (69%) versus Dukes' C (48%) patients (p = 0.09). On the other hand, Dukes' stage B + C patients with elevated preoperative levels of CEA or CA 19-9 had a significantly poorer DFS than patients with normal levels. For CEA levels below or above the cutoff the DFS was 74% versus 23% (p = 0.003); for CA 19-9 levels below or above the cutoff the DFS was 71% versus 33% (p = 0.004). In 54 patients with Dukes' stage B + C for whom preoperative levels of both CEA and CA 19-9 were available multivariate analysis revealed a decreasing risk of relapse in the following order: CEA and/or CA 19-9 elevated (chi-square 7.09; p = 0.008), CA 19-9 elevated (chi-square 6.27; p = 0.01), CEA elevated (chi-square 5.47; p = 0.02), and Dukes' C (chi-square 2.08; p = 0.15 n.s.). Hence, novel treatment protocols may have improved the disease-free survival, but the use of adjuvant chemotherapy and/or radiotherapy is of questionable benefit in patients who have elevated levels of CEA and/or CA 19-9 prior to treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10763141     DOI: 10.1177/172460080001500109

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   3.248


  7 in total

1.  Evaluation of preoperative serum markers for individual patient prognosis in stage I-III rectal cancer.

Authors:  Clemens Giessen; Dorothea Nagel; Maria Glas; Fritz Spelsberg; Ulla Lau-Werner; Dominik Paul Modest; Marlies Michl; Volker Heinemann; Petra Stieber; Christoph Schulz
Journal:  Tumour Biol       Date:  2014-07-17

2.  Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002).

Authors:  Christian Weissenberger; Michael Geissler; Florian Otto; Annette Barke; Karl Henne; Georg von Plehn; Alex Rein; Christine Muller; Susanne Bartelt; Michael Henke
Journal:  World J Gastroenterol       Date:  2006-03-28       Impact factor: 5.742

3.  Preoperative serum markers for individual patient prognosis in stage I-III colon cancer.

Authors:  Clemens Giessen-Jung; Dorothea Nagel; Maria Glas; Fritz Spelsberg; Ulla Lau-Werner; Dominik Paul Modest; Christoph Schulz; Volker Heinemann; Dorit Di Gioia; Petra Stieber
Journal:  Tumour Biol       Date:  2015-05-08

4.  Prognostic value of pretreatment serum carbohydrate antigen 19-9 level in patients with colorectal cancer: A meta-analysis.

Authors:  Zhan Yu; Zhen Chen; Jian Wu; Zhong Li; Yugang Wu
Journal:  PLoS One       Date:  2017-11-15       Impact factor: 3.240

5.  The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line.

Authors:  Ondrej Fiala; Petr Hosek; Ondrej Sorejs; Vaclav Liska; Tomas Buchler; Alexandr Poprach; Radek Kucera; Ondrej Topolcan; Monika Sedivcova; Jindrich Finek
Journal:  J Cancer       Date:  2018-10-20       Impact factor: 4.207

6.  Survival Rate of Colorectal Cancer in Eastern Mediterranean Region Countries: A Systematic Review and Meta-Analysis.

Authors:  Hossein-Ali Nikbakht; Soheil Hassanipour; Layla Shojaie; Mohebat Vali; Saber Ghaffari-Fam; Mousa Ghelichi-Ghojogh; Zahra Maleki; Morteza Arab-Zozani; Elham Abdzadeh; Hamed Delam; Hamid Salehiniya; Maryam Shafiee; Salman Mohammadi
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

Review 7.  A systematic review and meta-analysis of diagnostic and prognostic serum biomarkers of colorectal cancer.

Authors:  Zhongyu Liu; Yingchong Zhang; Yulong Niu; Ke Li; Xin Liu; Huijuan Chen; Chunfang Gao
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.